Metal Metabolism, Inborn Errors: Clinical Trials

265 trials for Metal Metabolism, Inborn Errors, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

136 completed, 41 recruiting, 29 unknown, 20 active not recruiting. 53 Phase 2, 37 Not applicable, 33 Phase 1, 29 Phase 3, 14 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 253Completed 33, Active not recruiting 6, Recruiting 5, Terminated 3, Enrolling by invitation 2, Not yet recruiting 2, Withdrawn 2
Not applicable37Completed 17, Unknown 7, Recruiting 5, Active not recruiting 4, Not yet recruiting 2, Terminated 1, Withdrawn 1
Phase 133Completed 22, Recruiting 5, Active not recruiting 2, Not yet recruiting 2, Terminated 1, Unknown 1
Phase 329Completed 19, Active not recruiting 3, Terminated 3, Unknown 3, Recruiting 1
Phase 414Completed 6, Unknown 5, Withdrawn 2, Recruiting 1
Early Phase 15Recruiting 2, Completed 1, Terminated 1, Unknown 1

Follow Metal Metabolism, Inborn Errors: new trials by email Literature Review of Metal Metabolism, Inborn Errors trials Research Report on Metal Metabolism, Inborn Errors

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Clarify HPP: Disease Burden of HPP Patients in China
Hypophosphatasia (HPP)
RecruitingAstraZeneca2002026-09-262026-10-29
Trientine Tetrahydrochloride Administered Once a Day for the First Line Treatment of Wilson's Disease Patients.
TETA 4HCl formulation, D-Penicillamine - Wilson's Disease
Phase 3RecruitingOrphalan382026-09-032026-10-15
A Study of the Safety and Efficacy of Prime Editing (PM577) in Participants With Wilson Disease (WD)
PM577a - Wilson Disease, Wilson's Disease
Phase 1 / Phase 2RecruitingPrime Medicine, Inc.422026-09-012026-10-01
Morphology in Oral Rare Syndromes & Artificial Intelligence for Clinical Diagnosis
intra-oral 3D optical impression - Osteogenesis Imperfecta, Rare Bone Disorders
Not applicableNot yet recruitingUniversity Hospital, Bordeaux2402026-09-012026-06-24
GRACE II (General Retrospective Analysis of Commercial Experience With AGN1 LOEP)
AGN1 LOEP - Osteoporosis
Enrolling by invitationAgNovos Healthcare, LLC3052026-08-252026-10-30
NORTHERA (DROXIDOPA) for Dysautonomia in Pediatric Survivors of Menkes Disease
Droxidopa Oral Product, Placebo Control - Menkes Disease
Phase 1 / Phase 2RecruitingStephen G. Kaler62026-08-102026-10-05
Mitigate Immune-Mediated Loss of Therapeutic Response to Asfotase Alfa (STRENSIQ®) for Hypophosphatasia
methotrexate, rituximab, bortezomib - Hypophosphatasia
Phase 4WithdrawnAlexion Pharmaceuticals, Inc.2026-07-292025-12-18
Description of Renal Involvement in Wilson's Disease
full renal workup - Wilson Disease
RecruitingFondation Ophtalmologique Adolphe de Rothschild1502026-07-222026-10-01
Setmelanotide to Treat Obesity in a Patient With Pseudohypoparathyroidism Type 1a (PHP1a)
Setmelanotide - Pseudohypoparathyroidism Type 1a, Obesity
Phase 2Enrolling by invitationMassachusetts General Hospital12026-07-212026-07-23
Treatment Patterns, Biochemical Profiles and Clinical Outcomes in Adults With X-Linked Hypophosphatemia
No treatment given - X-linked Hypophosphatemia (XLH)
WithdrawnNovo Nordisk A/S2026-07-072026-08-28
Endocrine Dysfunction in Pediatric Wilson's Disease
Wilson's Disease
Not yet recruitingAssiut University302026-06-302025-10-06
Phase I/II Clinical Study to Evaluate the Safety, Tolerability and Efficacy of LY-M003 Injection in Adult Patients With Wilson's Disease
LY-M003 Injection - Wilson's Disease
Phase 1 / Phase 2Not yet recruitingLingyi Biotech Co., Ltd.182026-06-152026-07-02
A Study to Evaluate BBI-001 in Healthy Volunteers and in Patients With Hereditary Hemochromatosis
BBI-001, Placebo - Hereditary Hemochromatosis
Phase 1 / Phase 2RecruitingBond Biosciences342026-05-042026-05-13
Efficacy and Safety of Vamifeport in Adult Participants With Homeostatic Iron Regulator Gene (HFE)-Related Hereditary Hemochromatosis
Vamifeport, Placebo - Homeostatic Iron Regulator Gene-related Hereditary Hemochromatosis
Phase 2Active not recruitingCSL Behring842026-01-222026-10-21
Off Treatment Urinary Copper Excretion in Wilson Disease, Pilot Study
Wilson Disease
RecruitingYale University302026-01-082026-03-05
A Clinical Study on the Treatment of Wilson Disease With ATP7B mRNA/LNP (DSL101)
Group 1: DSL101 Low dose, Group 2: DSL101 Medium dose, Group 3: DSL101 High dose - Wilsons Disease
Early Phase 1RecruitingDSciLab Co., Ltd.182025-12-312026-01-20
Prescreening Study to Identify Potential Wilson Disease Participants for Gene-Editing Clinical Trial
Wilson Disease
Active not recruitingPrime Medicine, Inc.302025-12-292026-05-12
The Effect of Monoallelic Variants in the ALPL Gene on the Natural Course of Hypophosphatasia in Russia
Hypophosphatasia
RecruitingAstraZeneca552025-12-292026-09-28
Multifaceted Assessment of Patients With Wilson's Disease in a Low-Resource Setting in Upper Egypt: Service Integration, Psychosocial Burden, Dietary Practices, and the Geo-Spatial Disease Map
KAB-pB Scores - Wilson's Disease
Not yet recruitingAssiut University662025-12-012025-11-21
Wilson's Disease Treated With D-Penicillamine: Characterization of Skin Damage Secondary to Treatment by Measuring Skin Elasticity
Preparation of forearm molds with SILFLO® silicone - Wilson Disease, D-Penicillamine
Not applicableRecruitingCentre Hospitalier Universitaire de Saint Etienne1202025-11-282026-01-23

Showing 20 of 265. Sign in to see all of them.

Narrower conditions

Hepatolenticular Degeneration (79)  ·  Hemochromatosis (54)  ·  Familial Hypophosphatemic Rickets (49)  ·  Hypophosphatasia (46)  ·  Pseudohypoparathyroidism (23)  ·  Iron Overload (19)  ·  Rickets (19)  ·  Osteomalacia (16)  ·  Bone Diseases (14)  ·  Rare Diseases (11)  ·  Hypophosphatemia (9)  ·  Menkes Kinky Hair Syndrome (9)  ·  Thalassemia (8)  ·  Genetic Diseases, Inborn (6)  ·  Hypoparathyroidism (6)

Broader conditions

Nutritional and Metabolic Diseases (264)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (263)  ·  Metabolic Diseases (262)  ·  Metabolism, Inborn Errors (261)  ·  Genetic Diseases, Inborn (259)  ·  Musculoskeletal Diseases (99)  ·  Nervous System Diseases (97)  ·  Central Nervous System Diseases (91)  ·  Brain Diseases (90)  ·  Heredodegenerative Disorders, Nervous System (88)  ·  Bone Diseases, Metabolic (87)  ·  Brain Diseases, Metabolic (87)  ·  Brain Diseases, Metabolic, Inborn (87)  ·  Calcium Metabolism Disorders (86)

Interventions

burosumab (20)  ·  asfotase alfa (16)  ·  Phlebotomy (8)  ·  tetrathiomolybdate (6)  ·  Deferoxamine (5)  ·  Trientine (5)  ·  Deferasirox (4)  ·  Standard of Care (4)  ·  Theophylline (4)  ·  Deferiprone (3)  ·  Penicillamine (3)  ·  Blood Specimen Collection (2)  ·  Calcitriol (2)  ·  Cinacalcet (2)  ·  Dichlorphenamide (2)

Sponsors

Alexion Pharmaceuticals, Inc. (34)  ·  Kyowa Kirin Co., Ltd. (10)  ·  Rennes University Hospital (8)  ·  Fondation Ophtalmologique Adolphe de Rothschild (7)  ·  Assistance Publique - Hôpitaux de Paris (6)  ·  Hospices Civils de Lyon (6)  ·  Kyowa Kirin, Inc. (6)  ·  Orphalan (6)  ·  Yale University (6)  ·  Kyowa Kirin Pharmaceutical Development Ltd (5)  ·  National Heart, Lung, and Blood Institute (NHLBI) (5)  ·  Ultragenyx Pharmaceutical Inc (5)  ·  Vanderbilt University Medical Center (5)  ·  Assiut University (4)  ·  National Center for Research Resources (NCRR) (4)

Countries

United States (101)  ·  France (56)  ·  United Kingdom (46)  ·  Germany (34)  ·  Canada (27)  ·  China (24)  ·  Italy (20)  ·  Spain (19)  ·  Australia (17)  ·  Denmark (17)  ·  Japan (13)  ·  Belgium (10)  ·  Netherlands (10)  ·  Poland (10)  ·  Turkey (Türkiye) (10)

Top investigators

Eugene S. Swenson, MD, PhD (4)  ·  Jaclyn Tamaroff, MD (3)  ·  Amy Zhang, PhD (2)  ·  Chaohui Yu, PhD (2)  ·  Curtis Scribner, MD (2)  ·  Eva Rombout, MD (2)  ·  George J. Brewer (2)  ·  Lothar Seefried, MD (2)  ·  Adrian Gadano, MD (1)

Results publications

PMID 39151033, PMID 26529632, PMID 32417537, PMID 32721016, PMID 32762706, PMID 40962182, PMID 25919461, PMID 27699270, PMID 36854566, PMID 15923132, PMID 16278898, PMID 16675931, PMID 17164301, PMID 17482283, PMID 17652219, PMID 17959863, PMID 18055982, PMID 18252944, PMID 18256395, PMID 18351337, PMID 18752978, PMID 19194885, PMID 19863539, PMID 20497190, PMID 20610593, PMID 20652413, PMID 20658587, PMID 20719837, PMID 21078496, PMID 21183586, PMID 21525160, PMID 21826782, PMID 21848963, PMID 22134099, PMID 22144108, PMID 22180427, PMID 22318199, PMID 22340672, PMID 22397652, PMID 2265118, PMID 23861242, PMID 24030943, PMID 24385534, PMID 24569459, PMID 24914136, PMID 24916507, PMID 25029424, PMID 25281031, PMID 25284616, PMID 25345697

NIH funding

2014 (2), 2025 (2), 2016 (1), 2017 (1), 2018 (1), 2019 (1), K23DK101689 (1), P50AR054086 (1), R01DK088988 (1), R01DK100651 (1), R01DK117354 (1), R01DK137861 (1), R01HL061428 (1), R15HL058203 (1), R21AR061818 (1)